This represents the second federally funded
insurance plan, after the Veteran Administration (VA), to cover the
innovative therapy
BRIDGEWATER, N.J. and
NETANYA, Israel,
May 21,
2024 /PRNewswire/ -- Theranica, a neuromodulation
therapeutics company, today announced DC Medicaid's coverage of the
Nerivio® REN wearable, the first and only FDA-cleared,
non-drug, non-disruptive treatment for both acute attacks and
prevention of migraine with or without aura in adolescents and
adults ages 12 and older. This coverage will empower DC Medicaid
beneficiaries living with migraine with a non-invasive, drug-free
treatment option.
DC Medicaid is now the second federally
funded insurance plan to cover the Nerivio REN wearable for
migraine relief.
In addition to the VA, DC Medicaid is now the second federally
funded insurance plan to cover the Nerivio REN wearable, offering
life changing relief to people living with migraine. Nerivio
harnesses the natural power of the brain to abort migraine pain and
associated symptoms without drugs or disruption, so patients can
safely and effectively prevent and treat migraine and be present in
everyday life. DC Medicaid covers over 300,000 members in the
greater Washington D.C. area,
accounting for 45% of the District's population.
DC's Medicaid decision is significant in setting the course for
additional federally funded programs as well as commercial
insurance providers across the U.S. Earlier this year, Highmark
Inc. and Blue Cross Blue Shield North Dakota announced coverage for
Nerivio, leading the effort to increase access to effective
drug-free prescribed migraine treatments with clinical benefits
properly backed by high-quality data.
"I commend DC Medicaid's decision to cover the Nerivio REN
wearable for both acute and preventive treatment of migraines,
providing much-needed relief to underserved patients," said
Professor Christopher Gottschalk,
MD, FAHS, General Neurology Section Chief and Director of the
Headache & Facial Pain Center at Yale
University, and the Immediate Past President of the Alliance
for Headache Disorders Advocacy (AHDA) "By embracing clinically
proven, non-pharmacologic therapies such as a REN wearable, we're
not only improving patient outcomes but also advancing the standard
of care for people living with migraine."
"This is such great news," added Marc
DiSabella, DO, Director of the Headache Program at
Children's National Hospital in Washington D.C. "Now this treatment can be
used as first-line therapy in our young migraine patients with DC
Medicaid or managed health plans".
Many of the 40 million patients living with migraine in the U.S.
need a non-disruptive way to both treat and prevent migraine, and
having insurance coverage is paramount for most. Additionally, a
health economics outcome study published in The Journal of
Health Economics demonstrated significant savings to health
insurance companies, estimated at $10,000 in annual cost per member, when covering
Nerivio for prevention of migraine.
"A recent report from the Headache and Migraine Policy Forum
states that eight in 10 patients say limited access to care leads
to more frequent and severe migraine attacks," said Alon Ironi, CEO of Theranica. "This underscores
Theranica's commitment to providing a non-disruptive and drug-free
migraine treatment and also highlights the importance of DC
Medicaid's decision to expand access to clinically proven
treatments. The in-depth clinical evaluation by Highmark in
2022-2023 has paved the way for DC Medicaid, BCBS North Dakota, and
other payers to follow suit and prioritize the well-being of their
members living with migraine."
For more information about the Nerivio REN wearable and to
download a prescription form, please visit Nerivio.com.
About Nerivio
Controlled by a smartphone app and
self-administered, the Nerivio REN wearable is a complete migraine
care treatment that wraps around the upper arm and uses sub-painful
Remote Electrical Neuromodulation (REN) to activate nociceptive
nerve fibers in the arm. These fibers send signals that trigger a
descending pain management mechanism in the brain called
conditioned pain modulation (CPM), which turns off migraine pain
and associated symptoms without medication. In simpler terms, the
upper arm is stimulated to unleash a natural process in the brain
to abort or relieve migraine headaches and other associated
symptoms. Each treatment lasts 45 minutes and is applied every
other day for prevention or at the start of a migraine attack for
acute treatment.
About Theranica
Theranica is a neuromodulation
therapeutics company dedicated to creating effective, safe,
affordable, low-side-effect therapies for idiopathic pain
conditions. The company's award-winning flagship wearable,
Nerivio®, is the first FDA-cleared prescribed migraine REN wearable
for acute and/or preventive treatment of migraine. Nerivio has been
used in more than 650,000 migraine treatments in the U.S.,
including by adolescents and veterans. Learn more by visiting our
websites, theranica.com and nerivio.com, and following us
on LinkedIn, X (formerly Twitter), Instagram and
Facebook.
#NoMatterWhat
Theranica Contact:
Ronen Jashek
ronenj@theranica.com
+972-72-390-9750
Media Contact:
Jennifer
Sefakis
Grey Matter Marketing
jennifer@greymattermarketing.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/dc-medicaid-becomes-the-first-medicaid-plan-to-cover-the-nerivio-ren-wearable-a-non-drug-treatment-for-migraine-302150532.html
SOURCE Theranica